VITA 34 stock analysis
VITA 34 (0NLV) Share Price & Analysis
0NLV Stock Chart & Stats
- Day’s Range
- EUR 2.46 - EUR 2.46
- 52-Week Range
- EUR 2.31 - EUR 7.00
- Previous Close
- EUR 2.31
- Volume
- N/A
- Average Volume (3M)
- 2
- Market Cap
- EUR 42.71M
- Enterprise Value
- EUR 73.56M
- Total Cash (Recent Filing)
- EUR 12.45M
- Total Debt (Recent Filing)
- EUR 23.03M
- Price to Earnings (P/E)
- ―
- Beta
- 0.37
- Next Earnings
- Nov 30, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth
Sustained revenue expansion indicates improving demand for VITA 34’s biological-material collection and storage services. Continued top-line growth can improve operating leverage, support investment in the platform, and strengthen the company’s ability to absorb fixed costs over the next several quarters.
Improving Profitability
The recovery in gross margin and the return to positive EBITDA show meaningful improvement in the underlying operating model. If maintained, stronger margins should increase cash conversion potential, provide greater flexibility for growth investment, and move the company closer to sustainable profitability.
Positive Cash Generation
Positive operating and free cash flow provide an important source of internal funding despite the reported net loss. This supports ongoing operations and reduces immediate reliance on external capital, although the benefit will be more durable if the recent improvement proves consistent.
Bears Say
Persistent Losses
VITA 34 has not yet converted its improving revenue and margins into positive bottom-line earnings. Continued net losses can consume the company’s limited equity cushion, restrict reinvestment capacity, and make financial performance more dependent on further operational improvement.
Elevated Leverage
The sharp increase in leverage and thin equity base materially reduce financial flexibility. A smaller capital cushion leaves less capacity to absorb weaker results, fund expansion internally, or manage obligations without additional financing, making balance-sheet risk a durable constraint on the business.
Cash-flow Inconsistency
Although current cash generation is positive, the historical volatility and sharply negative latest free-cash-flow growth indicate that the improvement may not yet represent a stable run rate. Inconsistent conversion of earnings and operations into cash could complicate debt management and investment planning.
0NLV FAQ
What was VITA 34’s price range in the past 12 months?
What is VITA 34’s market cap?
When is VITA 34’s upcoming earnings report date?
How were VITA 34’s earnings last quarter?
Is VITA 34 overvalued?
Does VITA 34 pay dividends?
What is VITA 34’s EPS estimate?
How many shares outstanding does VITA 34 have?
What happened to VITA 34’s price movement after its last earnings report?
Which hedge fund is a major shareholder of VITA 34?
What is the TipRanks Smart Score and how is it calculated?
VITA 34 Stock Smart Score
Company Description
VITA 34
FamiCord AG is dedicated to the collection, processing, and long-term storage of stem cells derived from umbilical cord blood and tissue. Its operations span Germany, Spain, and global markets. The company actively develops a range of advanced therapeutic solutions, including cell and gene therapies, specialized cell therapeutic procedures, cryopreservation of a patient's own immune cells, and CAR-T cell technology. Furthermore, FamiCord manufactures advanced therapy medicinal products (ATMPs) based on mesenchymal stem cells for experimental applications by specialized medical institutions. It also preserves stem cells from perinatal tissues and adult body fat, and provides contract manufacturing for pharmaceutical intermediates. Founded in 1997, FamiCord is headquartered in Leipzig, Germany.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Jakub Julian Baran
- Employees
- 723
- Website
- www.famicord.com
- Address
- Perlickstrasse 5, Leipzig, SX, 04103, DE
VITA 34 (0NLV) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 1 | 15 |
| Technical Analysis | 6 | 1 | 3 |
| Moving Averages | 0 | 0 | 12 |

